87 results on '"Chiaravalli M"'
Search Results
2. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma
3. Primary cilia sense glutamine availability and respond via asparagine synthetase.
4. 1517P Isolated LUng Metastases in pancreatic AdenoCArcinoma patients in a multicenter Italian cohort: The LU.M.A.CA study
5. P-97 DNA damage repair (DDR) germline mutations (GMs) in pancreatic ductal adenocarcinoma (PDAC): A mono-institutional retrospective study
6. P-148 The impact of second-line treatment after fist-line cisplatin plus gemcitabine in advanced biliary tract cancers: A mono-institutional retrospective study
7. P-155 Adjuvant therapy (AT) in patients (pts) with radically resected ampullary adenocarcinoma (AA): A monocentric retrospective analysis
8. P-74 The impact of first-line chemotherapy in elderly patients with advanced pancreatic cancer: A mono-institutional retrospective study
9. 2062P The psychological distress (PsyD) evaluation in pancreatic cancer (PC) patients (pts): A mono-institutional analysis
10. 1679P Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
11. 1635P Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic ductal adenocarcinoma patients
12. P-275 FOLFOX versus FOLFIRI as second-line treatment after cisplatin-gemcitabine in patients with advanced biliary tract cancers
13. P-110 Epidemiological and clinicopathological features of early- (EOPC) and late-onset pancreatic cancer (LOPC) patients (pts): A mono-institutional retrospective analysis
14. P-164 The role of response as a predictor of improved outcome in advanced pancreatic cancer patients treated with first-line gemcitabine plus nab-paclitaxel
15. P-152 The impact of 2nd-line treatment after 1st-line gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients
16. Rumen inoculum collected from cows at slaughter or from a continuous fermenter and preserved in warm, refrigerated, chilled or freeze-dried environments for in vitro tests
17. Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies
18. Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma
19. Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in unresectable or borderline resectable pancreatic adenocarcinoma
20. A randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in unresectable or borderline resectable pancreatic adenocarcinoma: the ghost regimen strikes back
21. The responsibilities of a health volunteer rescuer: ethical and medical legal considerations
22. Perimortem Cesarean Section on an Ambulance: case report and bioethical considerations
23. La responsabilità degli operatori del sistema sanitario di emergenza-urgenza
24. The responsibilities of an health volunteer rescuer: ethical and medical-legal considerations
25. PI3K-C2α regulates Polycystin-2 ciliary entry to prevent kidney cyst formation
26. Aspetti etico-deontologici e medico legali dell'emergenza sanitaria. La responsabilità dell'Infermiere volontario
27. 739P - Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma
28. PRK Excimer Laser Treatments: Our Experience on Four Years Follow Up
29. Comparison between optical coherence biometric method and the ultrasonic biometric method
30. PROPOSTA DI UTILIZZO DI UN MODELLO ANIMALE E DI UNO ARTIFICIALE PER LA RACCOLTA SISTEMATICA DEI PATTERNS LESIVI SUPERFICIALI DI ARMI BIANCHE
31. 681P - Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in unresectable or borderline resectable pancreatic adenocarcinoma
32. B01* - A randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in unresectable or borderline resectable pancreatic adenocarcinoma: the ghost regimen strikes back
33. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial
34. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial
35. Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways
36. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma
37. The centrosomal OFD1 protein interacts with the translation machinery and regulates the synthesis of specific targets
38. 2-Deoxy-D-glucose ameliorates PKD progression
39. Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients.
40. Inhibition of asparagine synthetase effectively retards polycystic kidney disease progression.
41. Primary cilia sense glutamine availability and respond via asparagine synthetase.
42. Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers.
43. SARS-CoV-2 on Ocular Surfaces in a Cohort of Patients With COVID-19 From the Lombardy Region, Italy.
44. TWEAK Signaling Pathway Blockade Slows Cyst Growth and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
45. The morphology of choroidal neovascularization in chronic central serous chorioretinopathy presenting with flat, irregular pigment epithelium detachment.
46. Multidrug regimens for treatment of older patients with metastatic pancreatic cancer.
47. Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification.
48. Increased mitochondrial fragmentation in polycystic kidney disease acts as a modifier of disease progression.
49. Polycystin-1 Regulates Actomyosin Contraction and the Cellular Response to Extracellular Stiffness.
50. Comparison of Faecal versus Rumen Inocula for the Estimation of NDF Digestibility.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.